Publications by authors named "Anshul Shah"

Claim this Profile
D
Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany.
Rupesh Subash, Cecilia Duan, Anshul Shah, Dionne M Hines, Michelle Zhang

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of clinical and economic impact of rivaroxaban plus aspirin vs. aspirin alone as a secondary prophylaxis in patients with chronic and symptomatic peripheral arterial disease in the United States.
Anshul Shah, Firas Dabbous, Surbhi Shah, Veronica Ashton, Akshay Kharat

J Med Econ· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of atrial fibrillation screening in Canadian community practice.
Jason G Andrade, Anshul Shah, Richard Godin, Tereza Lanitis, Thitima Kongnakorn

Heart Rhythm O2· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Andreas Nikolaou, Apoorva Ambavane, Anshul Shah, Wenkang Ma, Jon Tosh

Expert Rev Hematol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Anshul Shah, Jonathan C Tosh, Apoorva Ambavane, Andreas Nikolaou, Cosmina Hogea

Clinicoecon Outcomes Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Luis Hernandez, Hiroyo Kuwabara, Anshul Shah, Kaoru Yamabe, Heather Burnett

Pharmacoeconomics· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.
Apoorva Ambavane, Shuo Yang, Michael B Atkins, Sumati Rao, Anshul Shah

Immunotherapy· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States.
Luis Hernandez, Anshul Shah, Qi Zhao, Dejan Milentijevic, Akshay Kharat

Am Health Drug Benefits· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
Jingbo Yu, Shreekant Parasuraman, Anshul Shah, Daniel Weisdorf

Curr Med Res Opin· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion.
Steven E Bradshaw, Smeet Gala, Merena Nanavaty, Anshul Shah, Mkaya Mwamburi

BMC Ophthalmol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension.
Chakkarin Burudpakdee, Anshul Shah, Vijay N Joish, Christine Divers, Avin Yaldo

Am Health Drug Benefits· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis